|
Originally published In Press as doi:10.1074/jbc.M101233200 on April 17, 2001
J. Biol. Chem., Vol. 276, Issue 27, 25279-25286, July 6, 2001
Pdx1 Level Defines Pancreatic Gene Expression Pattern and
Cell Lineage Differentiation*
Haiyan
Wang §,
Pierre
Maechler ,
Beate
Ritz-Laser¶,
Kerstin A.
Hagenfeldt ,
Hisamitsu
Ishihara ,
Jacques
Philippe¶, and
Claes B.
Wollheim §
From the Division of Clinical Biochemistry and the
¶ Diabetes Unit, Department of Internal Medicine, Geneva
University Medical Center, CH-1211 Geneva 4, Switzerland
Received for publication, February 8, 2001, and in revised form, March 21, 2001
 |
ABSTRACT |
The absence of Pdx1 and the expression of brain-4
distinguish -cells from other pancreatic endocrine cell lineages. To
define the transcription factor responsible for pancreatic cell
differentiation, we employed the reverse
tetracycline-dependent transactivator system in INS-I
cell-derived subclones INSr and INSr to achieve tightly
controlled and conditional expression of wild type Pdx1 or its
dominant-negative mutant, as well as brain-4. INSr cells express not only insulin but also glucagon and brain-4, while INSr
cells express only insulin. Overexpression of Pdx1 eliminated glucagon
mRNA and protein in INSr cells and promoted the expression of
-cell-specific genes in INSr cells. Induction of
dominant-negative Pdx1 in INSr cells resulted in differentiation
of insulin-producing -cells into glucagon-containing -cells
without altering brain4 expression. Loss of Pdx1 function alone in
INSr cells, which do not express endogenous brain-4 and glucagon,
was also sufficient to abolish the expression of genes restricted to
-cells and to cause -cell differentiation. In contrast, induction
of brain-4 in INSr cells initiated detectable expression of glucagon
but did not affect -cell-specific gene expression. In conclusion, Pdx1 confers the expression of pancreatic -cell-specific genes, such
as genes encoding insulin, islet amyloid polypeptide, Glut2, and
Nkx6.1. Pdx1 defines pancreatic cell lineage differentiation. Loss of
Pdx1 function rather than expression of brain4 is a prerequisite for
-cell differentiation.
 |
INTRODUCTION |
The pancreatic islets of Langerhans are composed of four different
endocrine cell types: glucagon- ( ), insulin- ( ), somatostatin- ( ), and pancreatic polypeptide-producing cells (1). These four
endocrine cell lineages are differentiated from a common neurogenin3-expressing precursor (2-6). Targeted disruption of mouse
genes encoding various transcription factors has demonstrated their
importance in the control of islet cell development and differentiation. The homozygous deletion of the
Pdx1/Ipf1/Idx1/Stf1 gene in mice (7, 8) and in a
patient (9) causes pancreas agenesis. In neuroD-null mice,
the endocrine ( , , and ) cell mass is markedly reduced (10).
In Isl1-deficient mice, the dorsal pancreatic mesenchyme and
four hormone-producing endocrine cell lineages are deleted (11).
Homozygous disruption of the Nkx2.2 gene in mice results in
reduced and pancreatic polypeptide cell mass as well as defective
-cell differentiation (12). Pax6 is indispensable for
-cell development (13, 14), whereas homozygous
Pax4-null mice lack - and -cells (15).
Nkx6.1 is required for mature -cell differentiation and
-cell neogenesis during the secondary transition (16).
The -cell-specific inactivation of the Pdx1 gene in mice
has revealed that Pdx1 is required for maintaining the -cell
phenotype by positively regulating insulin expression and by repressing glucagon expression (17). Furthermore, brain4 has been suggested to
confer the pancreatic -cell specificity (18). The absence of Pdx1
and the expression of brain4 are characteristics of the mature islet
-cell lineage (5, 6, 8, 18-20). Nkx6.1 is exclusively expressed in
islet -cells after embryonic day 13 (17, 21, 22) and is required for
mature -cell differentiation (16). Pax4, which is expressed only
transiently in the fetal pancreas and functions as a transcriptional
repressor of the glucagon promoter, plays a significant role in the
development and differentiation of islet / cells (15, 23-25). It
has been demonstrated that Pdx1 binds to the promoters of the Nkx6.1
and Pax4, and Pdx1 is also necessary for Nkx6.1 expression (17, 25,
26). However, the correlation of Pdx1 function with the expression of
brain4 and Pax4 in the transcriptional hierarchy has not been well defined.
The pluripotent property of islet tumor cells has been described and
used as a model to study islet cell differentiation and to identify
islet cell-specific transcription factors (18, 20, 21, 27-29). INS-1
cells, which express endogenous pancreatic transcription factors Pdx1,
neuroD, Isl1, Pax4, Pax6, Nkx2.2, Nkx6.1, HNF1 , and HNF4 (30) and
display differentiation plasticity, would be suitable for elucidating
the function of transcription factors in islet cell differentiation.
The present study was designed to define the role of Pdx1 and brain4 in
the regulation of pancreatic cell lineage differentiation using
INS-1-derived stable cell lines expressing Pdx1, its dominant-negative
mutant (DN1-Pdx1), or brain4
under the control of the reverse tetracycline-dependent transactivator (rtTA) (31). The established INS-1 subclones would also
allow us to pinpoint the Pdx1-specific downstream target genes.
 |
EXPERIMENTAL PROCEDURES |
Cloning of the Rat Brain4 cDNA, Construction of Plasmids, and
Generation of Stable Cell Lines--
The rat insulinoma INS-1 cell
line-derived stable clones were cultured in RPMI 1640 in 11.2 mM glucose (30), unless otherwise indicated. The first-step
stable clones INSr and INSr , which express the reverse
tetracycline-dependent transactivator, were reported
previously as INS-r3 and INS-r9, respectively (32). Plasmids used in
the secondary stable transfection were constructed by subcloning the
cDNAs encoding the mouse Pdx1 (kindly supplied by Dr. H. Edlund,
Umea, Sweden), its dominant-negative mutant (DN-Pdx1), and the
rat brain4 into the expression vector PUHD10-3 (a kind gift from Dr.
H. Bujard). DN-Pdx1 (truncated mutation lacking the first 79 amino
acids) was PCR-amplified from Pdx1 using the following primers:
5'-gcaggatccgctcacctccaccaccaccttccagct-3' and
5'-ggcagatctggccattagcttggcatcagaagc-3'. The PCR fragment was subcloned
into modified pcDNA3.1myc (Invitrogene) and sequenced. The
rat brain4 cDNA was cloned by reverse transcription-PCR
using RNA from freshly isolated rat islets and the following primers: 5'-gaccatggccacagctgcctc-3' and 5'-tgcagcgggccacctccttg-3'. The PCR
product was inserted into the pGEM-T Easy Vector
(Promega/Catalys) according to the manufacturer's protocol and
sequenced. The stable transfection and the clone selection and
screening procedures were described previously (32).
Immunoblot and Immunofluorescence--
Immunoblotting procedures
were performed as described previously using enhanced chemiluminescence
(Pierce) for detection (30). The dilution for antibody against
Pdx1 C terminus (a kind gift from Dr. H. Edlund) was 1:5,000.
For immunofluorescence cells were grown on polyornithine-treated glass
coverslips for 1 day prior to 4 days of treatment with 500 ng/ml
doxycycline. The cells were then washed, fixed in 4% paraformaldehyde,
and permeabilized with 0.1% Triton X-100 in phosphate-buffered saline
containing 1% bovine serum albumin. The preparation was then blocked
with phosphate-buffered saline-bovine serum albumin before incubating
with the first antibodies mouse monoclonal anti-human insulin
(1:1,000 dilution; from Sigma) and rabbit polyclonal anti-porcine
glucagon (1:2,500 dilution) (33), followed by the second antibody
labeling. The resultant immunofluorescence was viewed using a Zeiss
laser scan confocal 410 microscope (Zurich, Switzerland).
Nuclear Extract Preparation and Electrophoretic Mobility Shift
Assay (EMSA)--
Nuclear extracts from INS-1 cells grown in culture
medium with or without 500 ng/ml doxycycline for 24 h and from
BHK-21 cells transfected with various expression plasmids were
prepared according to Schreiber et al. (34). The
following double-stranded oligonucleotides were used as probes: the rat
insulin I FLAT element 5'-GATCTTGTTAATAATCTAATTACC-3' (35, 36)
and the rat glucagon G1 element (37). EMSA procedures including
conditions for probe labeling, binding reactions, unlabeled probe
competition, and antibody supershift were performed as previously reported (37). Polyclonal antibodies raised against Pdx1 and Pax-6 were
generously provided by H. Edlund and S. Saule, respectively.
Cell Extract Fractionation--
Cells in 10-cm diameter dishes
were cultured with or without 500 ng/ml doxycycline for 24 h at
2.5, 6, 12, and 24 mM glucose. After washing twice with
ice-cold phosphate-buffered saline, the cells were suspended and
allowed to swell for 15 min at 4 °C in 400 µl of hypotonic buffer
composed of 20 mM Tris (pH 7.4), 5 mM EDTA, 2 mM dithiothreitol, and 0.2 mM
phenylmethylsulfonyl fluoride. After 3 cycles of freeze-thaw, the
cytosolic proteins (supernatant) were separated from the nuclear
fraction (pellet) by centrifugation. The nuclear proteins were further
isolated from the pellet according to Schreiber et al.
(34).
Total RNA Isolation and Northern Blotting--
Cells in 10-cm
diameter dishes were cultured in normal (11.2 mM) glucose
medium with or without 500 ng/ml doxycycline for the indicated times,
followed by an additional 8 h in culture medium with 2.5, 6, 12, and 24 mM glucose. Total RNA was extracted and blotted to
nylon membranes as described previously (32). The membrane was
prehybridized and then hybridized to 32P-labeled random
primer cDNA probes as previously described (38). To ensure equal
RNA loading and even transfer, all membranes were stripped and
rehybridized with "house-keeping gene" probes such as -actin or
cyclophilin. cDNA fragments used as probes for glucokinase, Glut2,
insulin, Pdx1, and brain4 mRNA detection were digested from
corresponding plasmids. cDNA probes for rat islet amyloid polypeptide (IAPP), somatostatin, glucagon, Nkx6.1, Nkx2.2,
Pax4, Pax6, Isl1, and 2/NeuroD were prepared by reverse
transcription-PCR and confirmed by sequencing.
Transient Transfection and Luciferase Assay--
Transient
transfection experiments and luciferase reporter enzyme assays were
carried out as previously reported (39). To overexpress transcription
factors for EMSA, non-islet Syrian baby hamster kidney (BHK-21) cells
were transfected by the calcium phosphate precipitation using 10 µg
of expression plasmids encoding quail Pax6 (S. Saule, Institut Curie,
Paris, France), hamster Cdx-2/3 (M. S. German, University of
California, San Francisco, CA), and mouse Pdx1 or DN-Pdx1.
Cellular Insulin and Glucagon Content--
Cells in 24-well
dishes were cultured with or without 500 ng/ml doxycycline for 4 days.
The content of insulin and glucagon was determined after extraction
with acid ethanol or 0.2% Tween 20 in phosphate-buffered saline
containing 6 milliunits/ml aprotinin, respectively, following the
procedures of Wang et al. (39). Insulin was detected by
radioimmunoassay using rat insulin as standard (39), and glucagon was
measured with a glucagon assay kit (Linco, St. Charles, MO).
Insulin Secretion--
Cells in 24-well dishes were cultured for
2 days in INS-1 medium followed by 5 h of equilibration in 2.5 mM medium. Insulin secretion was measured in the presence
of 2.5, 6, 12, or 24 mM glucose using Krebs-Ringer
bicarbonate HEPES buffer as previously described (39).
 |
RESULTS |
Characterization of INS-1-derived Subclones Expressing the rtTA and
Establishment of Secondary Stable Lines Overexpressing Pdx1, DN-Pdx1,
or Brain4--
The rat insulinoma INS-1 cells were used as the
parental line for stable transfection of an expression plasmid encoding
the rtTA (31, 32). A clone termed INSr , which maintains the INS-1 -cell phenotype, and another clone called INSr , which
represents a hybrid of - and -cells, were used for the present
study. As shown in Fig. 1, INS-r and
INS-1 cells express predominantly the -cell-specific markers insulin
and IAPP. In contrast, INSr cells express not only insulin and
IAPP but also glucagon and brain4 (Fig. 1). Somatostatin mRNA was
abundantly expressed in freshly isolated islets but not detected in
parental INS-1 cells or derived clones (Fig. 1). Pdx1 mRNA was
present in both INSr and INSr lines (Fig. 1).

View larger version (40K):
[in this window]
[in a new window]
|
Fig. 1.
Characterization of INS-1-derived
INSr and INSr
subclones by Northern blot analysis of mRNA expression.
Total RNAs were extracted from freshly isolated rat islets, parental
INS-1 cells, and rtTA-expressing subclones INSr and INSr .
20-µg RNA samples were analyzed by hybridizing with the indicated
32P-labeled cDNA probes.
|
|
To study whether the production of glucagon in INSr cells is
correlated with the expression of brain4, we generated an
INSr -derived stable cell line expressing brain4 in a
doxycycline-inducible manner. The cDNA encoding brain4 was obtained
by reverse transcription-PCR using RNA from freshly isolated rat
islets, cloned into pGEM-T vector, and sequenced. To delineate the
Pdx1-specific target genes and the Pdx1-regulated islet cell lineage
differentiation, we also established both INSr - and
INSr -derived stable clones expressing Pdx1 or DN-Pdx1 under the
control of rtTA. DN-Pdx1 represents the epitope Myc-tagged
truncated Pdx1 mutant protein lacking the N-terminal transactivation
domain (the first 79 amino acids) (40). The clones, named
r -brain4-119, r -Pdx1-6, r -DN-Pdx1-28, r -Pdx1-21, and
r -DN-Pdx1-59, which expressed the transgenes at the highest level
after induction and showed only background expression under non-induced
conditions, were selected for the present study.
Both Pdx1 and DN-Pdx1 Proteins Translocated from the Cytoplasm to
the Nucleus in a Glucose-dependent Manner but Did Not
Change Molecular Mass--
It has been reported that glucose
stimulates translocation of Pdx1 from the cytoplasm or nuclear
periphery to the nucleus in human islets and MIN6 cells (41-43).
Macfarlane et al. (41) also demonstrated that the Pdx1
translocation is concomitant with a shift in molecular mass from 31 to
46 kDa, whereas Rafiq et al. (42) reported no such change.
We investigated the intracellular location of both endogenous Pdx1 and
induced Pdx1 using cytoplasmic and nuclear fractions prepared from
r -Pdx1-21 cells incubated in 2.5, 6, 12, and 24 mM
glucose, respectively, for 24 h (Fig. 2A). The majority of Pdx1
protein was present in the cytosolic fraction when r -Pdx1-21
cells were maintained at 2.5 mM extracellular glucose
concentration; however, in 6 mM glucose, Pdx1 predominantly translocated to the nuclear fraction (Fig. 2A). Similar
results were obtained using the r -Pdx1-6 line (data not shown). The
31-kDa form of Pdx1 described by Macfarlane et al. (41) was
not detected by Western blotting of the cytoplasmic fraction (Fig.
2A) or whole cell extracts (data not shown) from the
INS-1-derived clones. Nevertheless, the endogenous Pdx1 protein in
Min6-m9 cells (44) also translocated from the cytoplasm to the nucleus
in a glucose-dependent manner but did not change molecular
mass (Fig. 2B). However, there is a clear difference in
glucose responsiveness in INS-1-derived cells compared with MIN6-m9
cells, because Pdx1 translocation was maximally stimulated at glucose
concentrations between 2.5 and 6 mM in INS-1-derived clones
(Fig. 2A), whereas glucose-regulated Pdx1 translocation
occurred over the full range from 2.5 to 24 mM glucose in
MIN6-m9 cells (Fig. 2B). The induced DN-Pdx1 mutant protein
lacking the N-terminal transactivation domain translocated in a way
similar to endogenous Pdx1 in both r -DN-Pdx1-59 (Fig. 2C) and r -DN-Pdx1-28 (Fig. 2D) cells, in
agreement with the identification of the nuclear localization signal in
the Pdx1 homeodomain (45).

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 2.
Cellular translocation of Pdx1 and DN-Pdx1
proteins in response to incremental extracellular glucose
concentrations. Nuclear extracts and cytosolic proteins were
prepared from r -Pdx1-21 (A), MIN6-m9 (B),
r -DN-Pdx1-59 (C), and r -DN-Pdx1-28 (D)
cells cultured with or without 500 ng/ml doxycycline for 24 h at
the indicated glucose concentrations. 10 µg of protein from the
nuclear extracts or 100 µg of protein from the cytosolic fraction
were resolved via 9% SDS-polyacrylamide gel electrophoresis,
transferred to nitrocellulose, and immunoblotted with an antibody
against the Pdx1 C terminus. NE, nuclear extracts
from cells in 11.2 mM glucose; kD,
kilodaltons.
|
|
It is noteworthy that the glucose responsiveness, in terms of both Pdx1
translocation and insulin secretion in INSr -derived cells, was
equivalent to that in INSr -derived cells (Fig. 2, A,
C, and D and Table
I). The right shift of the
glucose-induced Pdx1 translocation in MIN6-m9 cells (Fig.
2B) corresponds to the right shift of the glucose-stimulated
insulin secretion in these cells (44) relative to INS-1-derived
cells (Fig. 2, A, C, and D and Table
I). Thus, half-maximal insulin secretion in MIN6-m9 cells was observed
at 15 mM glucose (44), whereas the value is 6 mM in the INS-1-derived clones (Table I). Whether or not there is a direct correlation between the glucose-induced Pdx1 translocation and the glucose-stimulated insulin secretion remains to
be established.
View this table:
[in this window]
[in a new window]
|
Table I
Glucose-stimulated insulin secretion in INSr - and INSr -derived
clones
The amount of insulin released over 30 min from INSr -derived
r -DN-Pdx1-59 clone and INSr -derived r -Pdx1-6 clone is
presented as percent of insulin content. Data from six independent
experiments are shown as means ± S.E.
|
|
Induction of Pdx1 Eliminates Glucagon Expression in INSr
Cells and Promotes -Cell-specific Gene Expression in INSr
Cells--
Quantitative Northern blotting was employed to study the
impact of induction of Pdx1 on the expression of INS-1 mRNAs at
extracellular glucose concentrations of 2.5, 6, 12, and 24 mM. As demonstrated in Fig.
3A, glucagon mRNA
expression in INSr cells was no longer detectable after induction
of Pdx1 for 48 h, whereas brain4 mRNA remained constant.
Overexpression of Pdx1 in r -Pdx1-21 cells slightly raised the
mRNA level of Nkx6.1 but had no significant effect on the mRNA
expression of Nkx2.2, Pax4, Pax6, Isl1, and 2/NeuroD (Fig.
1A). We also performed EMSA experiments with a probe
corresponding to the rat insulin I FLAT element, which contains the
Pdx1-binding site (35, 36). Using nuclear extracts from r -Pdx1-21
cells cultured with or without 500 ng/ml doxycycline for 24 h, we
found that induction of Pdx1 resulted in a dramatic increase
(>20-fold) in its binding activity to the rat insulin promoter (data
not shown). Unexpectedly, we did not see a concomitant rise in the
mRNA levels of insulin or IAPP (Fig. 3A). Interestingly, the insulin content in r -Pdx1-21 cells was increased by more than
2-fold ( Dox, 33.65 ± 1.37 ng/mg or protein versus +Dox, 74.55 ± 17.23 ng/mg of protein; p < 0.005) after 4 days induction of Pdx1, despite the fact that the insulin mRNA was
reduced by 32.6% under the same condition. In contrast, the glucagon
content in r -Pdx1-21 cells dropped by 94% ( Dox, 8.09 ± 1.51 ng/mg of protein versus +Dox, 0.48 ± 0.11 ng/mg of protein;
p < 0.001) after induction of Pdx1 for 4 days.
Consistently, the immunofluorescence double staining of r -Pdx1-21
cells showed that the glucagon expression was no longer detectable,
whereas the insulin level was concomitantly increased after doxycycline
induction for 4 days (Fig. 3B).

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 3.
Induction of Pdx1 eliminates endogenous
glucagon expression in r -Pdx1-21
cells and promotes -cell-specific gene
expression in r -Pdx1-6 cells.
A, Northern blot analysis of gene expression in
r -Pdx1-21 cells induced with 500 ng/ml doxycycline and cultured
first in normal (11.2 mM) glucose medium for 24 or 48 h and then incubated further for 8 h at the indicated glucose
concentrations. 20 µg of total RNA samples were analyzed by
hybridizing with indicated cDNA probes. B, double
immunofluorescence staining with anti-insulin serum (green)
and anti-glucagon serum (red) in r -Pdx1-21 cells
cultured in the absence ( Dox) or the presence (+Dox) of 500 ng/ml
doxycycline for 4 days. C, Northern blotting quantification
of gene expression in r -Pdx1-6 cells induced with indicated
concentrations of doxycycline and cultured in normal (11.2 mM) glucose medium for 48 h. Total RNA samples
extracted from two independent experiments were blotted in parallel to
demonstrate the consistency of the data. 20 µg of RNA per lane were
loaded and analyzed by hybridizing with the indicated cDNA probes.
GK, glucokinase.
|
|
As shown in Fig. 3C, the graded overexpression of Pdx1 in
r -Pdx1-6 cells caused a stepwise increase in the expression of Nkx6.1 mRNA. The expression of another -cell-specific marker, Glut2, was also slightly increased by induction of Pdx1 (Fig. 3C). Overexpression of Pdx1 alone is not sufficient to raise
the endogenous insulin and IAPP mRNA levels (Fig. 3C).
However, overexpression of Pdx1 may facilitate the biosynthesis of
insulin or the formation (or maturation) of insulin granules, because
doxycycline treatment for 4 days also significantly increased
the insulin content in r -Pdx1-6 cells without altering insulin
mRNA expression.2
Loss of Pdx1 Function Converts INSr and INSr Cells into
Glucagon-predominant -Cells Independent of Brain4
Expression--
We predicted that DN-Pdx1, which lacks the
transactivation domain but preserves an intact DNA-binding domain (40),
would exert its dominant-negative function by competing with endogenous Pdx1 for binding to the cognate site in the rat insulin promoter. Indeed, our EMSA experiments using nuclear extracts from
r -DN-Pdx1-59 cells showed that the binding activity of endogenous
Pdx1 to the rat insulin I FLAT element was abolished over 90%
after 24 h of induction of DN-Pdx1 (data not shown). The
expression of -cell-specific genes encoding insulin, IAPP, Glut2,
and Nkx6.1 was drastically reduced but not completely eliminated after
treatment of r -DN-Pdx1-59 cells with doxycycline for 4 days (Fig.
4A). Concomitantly, the glucagon transcript level in these cells increased 5- and 10-fold after
induction of DN-Pdx1 for 2 and 4 days, respectively, whereas brain4
mRNA expression was not altered (Fig. 4A). Similarly,
immunofluorescence confocal microscopy studies in r -DN-Pdx1-59
cells showed that the insulin-staining cells were lost by 90%, and the
glucagon-staining cells accounted for over 90% of the whole cell
population after treatment with doxycycline for 4 days (Fig.
4B). Accordingly, the insulin content in these cells
decreased by 72% (48.15 ± 8.81 versus 13.68 ± 1.56 ng/mg
of protein; p < 0.001), whereas the glucagon content
increased over 2-fold (35.77 + 7.69 versus 75.07 + 6.12 ng/mg of protein; p < 0.001). Induction of DN-Pdx1
had no significant effect on the mRNA expression of 2/NeuroD,
Pax4, Pax6, Nkx2.2, and Isl-1 (Fig. 4A), suggesting that
these pancreatic transcription factors are not Pdx1-specific target
genes.

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 4.
Induction of DN-Pdx1 in
r -DN-Pdx1-59 and
r -DN-Pdx1-28 cells converted the
insulin-producing -cell lineage into the
glucagon predominant -cell phenotype.
A, quantitative evaluation by Northern blotting of the gene
expression profile in r -DN-Pdx1-59 cells induced with 500 ng/ml
doxycycline and cultured first in normal (11.2 mM) glucose
medium for 2 or 4 days and then incubated further for 8 h at the
indicated glucose concentrations. 20 µg of total RNA samples were
analyzed by hybridizing with indicated cDNA probes. B,
double immunofluorescence staining with anti-insulin serum
(green) and anti-glucagon serum (red) in
r -DN-Pdx1-59 cells cultured with or without 500 ng/ml doxycycline
for 4 days. C, Northern blot analysis of gene expression
patterns in r -DN-Pdx1-28 cells induced with 500 ng/ml doxycycline
and cultured first in normal (11.2 mM) glucose medium for 4 or 7 days and then incubated further for 8 h at the indicated
glucose concentrations. 20 µg of total RNA samples were analyzed by
hybridizing with the indicated cDNA probes. GK,
glucokinase; WT, wild type.
|
|
We also performed quantitative Northern blot analysis to investigate
the consequences of DN-Pdx1 induction on the gene expression patterns
of r -DN-Pdx1-28 cells that do not express detectable endogenous
brain4. As shown in Fig. 4C, the expression of islet -cell-specific markers, insulin, IAPP, Glut2, and Nkx6.1 in
r -DN-Pdx1-28 cells was dramatically decreased in a
time-dependent manner (Fig. 4C). In contrast,
glucagon mRNA expression in r -DN-Pdx1-28 cells (Fig.
4C) rose from an undetectable background to a level
comparable with that of fully induced r -DN-Pdx1-59 cells (Fig.
4A), whereas brain4 mRNA remained undetectable (data not
shown) after induction of DN-Pdx1. These results demonstrate that
dominant-negative suppression of Pdx1 function alone is sufficient
to differentiate the insulin-predominant -cell lineage to the
glucagon-predominant -cell phenotype. The brain4 expression is not
required for this effect, although there is a time delay in glucagon
gene expression comparing r -DN-Pdx1-28 (Fig. 4C) with
r -DN-Pdx1-59 cells (Fig. 4A).
Although it has been proposed that Pdx1 regulates the human glucokinase
promoter activity (46), we found that the endogenous rat glucokinase
mRNA expression was unresponsive to Pdx1 function in r -Pdx1-6
(Fig. 3C), r -DN-Pdx1-28 (Fig. 4C),
r -Pdx1-21 (Fig. 3A), and r -DN-Pdx1-59 (Fig.
4A) cells.
Induction of Brain4 Is Sufficient for Initiating a Detectable Level
of Glucagon Expression in INS-r Cells but Not Mature -Cell
Differentiation--
To investigate whether loss of Pdx1 function is
necessary for -cell differentiation, we examined the gene expression
patterns in r -brain4-119 cells using Northern blot analysis. After
induction of brain4 at an extremely high level for 4 days, glucagon
mRNA expression was initiated to a detectable level (Fig.
5) that is, however, 10-20-fold lower
compared with that of r -DN-Pdx1-28 (Fig. 4C) and
r -DN-Pdx1-59 (Fig. 4A) cells under similar conditions. Unlike induction of DN-Pdx1, however, forced expression of brain4 did
not alter the mRNA levels of islet -cell-specific genes encoding insulin, IAPP, Nkx6.1, and Glut2 (Fig. 5). Pdx1 is not the up-stream transcriptional regulator of brain4 (Figs. 3A and
4A); conversely induction of brain4 did not affect the Pdx1
expression either (Fig. 5).

View larger version (58K):
[in this window]
[in a new window]
|
Fig. 5.
Induction of brain4 in the
r -brain4-119 clone triggered only a detectable
level of glucagon expression but did not suppress the
-cell-specific gene expression. Northern blot
analysis of gene expression in r -brain4-119 cells induced with 500 ng/ml doxycycline and cultured first in normal (11.2 mM)
glucose medium for 4 days and then incubated further for 8 h at
the indicated glucose concentrations. 20 µg of total RNA samples were
analyzed by hybridizing with the indicated cDNA probes.
GK, glucokinase.
|
|
Pdx1 Represses the Glucagon Promoter Activity, Binds the G1
Element, but Does Not Compete with Pax6 for DNA Binding--
To
investigate whether Pdx1 suppresses the glucagon promoter activity, we
performed transient transfection experiments in r -Pdx1-21 and
r -DN-Pdx1-59 lines using a reporter plasmid consisting of the
firefly luciferase gene driven by the rat glucagon promoter
( 350GlucagonLuc). As expected, induction of Pdx1 for 24 h
caused a 65% reduction ( Dox, 5.13 ± 1.68 light units/mg of protein
versus +Dox, 1.81 ± 0.4 light units/mg of protein; p < 0.005; six independent experiments) in the
luciferase reporter enzyme activity in r -Pdx1-21 cells
transfected with 350GlucagonLuc. Consistently, induction of DN-Pdx1
for 24 h in r -DN-Pdx1-59 cells resulted in a 5.8-fold
increase ( Dox, 3.66 ± 1.07 light units/mg of protein
versus +Dox, 21.4 ± 4.98 light units/mg of protein;
p < 0.001; six separate experiments) in the glucagon promoter activity.
To explore the possible mechanism underlying the repressive function of
Pdx1 on glucagon gene promoter activity, we performed EMSA experiments
using nuclear extracts from r -Pdx1-21 and r -DN-Pdx1-59 cells and the G1 element of the rat glucagon promoter that confers cell specificity (37). As shown in Fig.
6A, Pdx1 overexpressed in
r -Pdx1-21 cells formed a complex on G1 that migrated similarly to
the paired homeodomain protein Pax-6, a major G1-binding factor. Similarly, DN-Pdx1 from doxycycline-induced r -DN-Pdx1-59 cells interacted with the G1 element, and anti-Pdx1 antibodies specifically recognized both Pdx1 protein complexes (Fig. 6A). To assess
the affinity of DN-Pdx1 and Pax-6 for G1, we performed EMSA competition experiments. When BHK-21 nuclear extracts containing Pax-6 were mixed with DN-Pdx-1-containing extracts, Pdx1 formed a weaker complex
on G1-56 as compared with the individual binding reaction (Fig.
6B). Furthermore, a 10 times greater excess of cold G1-56 was required to compete for DN-Pdx1 than for Pax-6, indicating a better
affinity of Pax-6 for G1 as compared with DN-Pdx1. It has previously
been shown that Pdx1 has a lower affinity for G1 when compared with
Pax-6 but an affinity similar to that of Cdx-2/3, a homeodomain protein
interacting synergistically with Pax-6 on G1.3 Similarly, Cdx-2/3 and
DN-Pdx1 displayed comparable affinity for G1 (Fig. 6C).
However, because Pdx1 and DN-Pdx1 had opposite effects on glucagon
promoter activity, it is unlikely that Pdx1 exerts transcriptional
repression through its binding to the G1 element. Its ability to
interact with other pancreatic transcription factors at the protein
level could be an alternative explanation, because we found that Pdx1
suppressed the transactivation of Pax6 through protein-protein
interaction independent of DNA binding.3

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 6.
Pdx1 and DN-Pdx1 bind to the glucagon gene
promoter element G1. A, EMSA using nuclear extracts
from r -Pdx1-21 and r -DN-Pdx1-59 cells incubated for 24 h in the absence or presence of 500 ng/ml doxycycline. Both Pdx1 and
DN-Pdx1 were able to bind G1. Px6 and Px1
indicate the addition of anti-Pax-6 and anti-Pdx1 antibodies,
respectively. B and C, competition experiments
analyzing the relative affinity of DN-Pdx1 and Pax-6 or Cdx-2/3 for the
G1 element. Protein-DNA complexes formed with nuclear extracts from
BHK-21 cells overexpressing DN-Pdx1, Pax-6, or Cdx-2/3 were competed
for by the indicated molar excess of cold G1-56 oligonucleotides.
|
|
 |
DISCUSSION |
Establishment of an in Vitro Model of Islet Cell Lineage
Differentiation--
Overexpression of a transcription factor,
CCAAT/enhancer-binding protein , in a pancreatic tumor cell
line has recently been demonstrated to provoke the transdifferentiation
toward the hepatocyte phenotype (47). In fact, the differentiation
potential and the multihormonal phenotype of islet tumor cells have
been known for a long time (27, 28). We found that rat insulinoma INS-1
cells also display high plasticity of differentiation, and we could actually detect by reverse transcription-PCR (data not shown) the
mRNAs of four islet hormones but not the exocrine marker, p48 (48).
In addition, we demonstrated that INS-1 cells express multiple
endogenous pancreatic transcription factors including Pdx1, Nkx6.1,
Nkx2.2, Pax4, Pax6, 2/NeuroD, and Isl1 (30), which are important for
regulation of islet cell differentiation and gene expression (49).
Therefore, the INS-1 cells represent neither pancreatic precursor cells
nor mature differentiated mono-hormone-producing islet cells. We
defined, by quantitative Northern blot analysis, two rtTA-expressing
INS-1-derived subclones termed INSr , expressing predominantly
insulin, and INSr , producing both insulin and glucagon. However,
we did not obtain any clone showing predominantly the -cell,
-cell, or pancreatic polypeptide cell phenotype. We implemented the
doxycycline-inducible system (Tet-on) (31) in INSr and INSr
lines to study the role of Pdx1 and brain4 in the regulation of islet
cell lineage differentiation and gene expression. Using the inducible
cell line rather than two distinct stable clones enabled us to tightly
control the level of transgenes and also to precisely quantify the gene
expression patterns under induced and non-induced conditions. It is
important to note that doxycycline itself, or the induction of an
irrelevant protein, had no effect on mRNA expression, insulin
secretion, and insulin content in INS-1 cells (30, 32). We also
demonstrated the differentiation plasticity of these cell lines by
immunofluorescence double staining with antibodies against insulin and glucagon.
Glucose Regulates the Cellular Translocation of Pdx1 Protein
without Altering Its Molecular Mass--
The present study supports
the previous reports that glucose stimulates translocation of Pdx1 from
the cytoplasm or nuclear periphery to the nuclei (41, 42). In addition,
we found that the majority of Pdx1 protein is located in the nucleus at
physiological concentrations of glucose (6 mM). During
starvation associated with hypoglycemia, Pdx1 would be transported out
of the nuclei, which may prevent the -cell from producing excessive
insulin. Although Macfarlane et al. (41) reported a shift in
the molecular mass of Pdx1 (from 31 to 46 kDa) concomitant with the
glucose-stimulated Pdx1 translocation, our Western blotting data
demonstrated that Pdx1 protein migrated at a constant molecular mass of
46 kDa irrespective of the glucose concentration. Our results are in
agreement with another study by Rafiq et al. (42). The
nuclear localization signal of Pdx1 has been identified as part of the
homeodomain (45). This explains why the translocation of DN-Pdx1
lacking the N-terminal transactivation domain resembled that of wild
type Pdx1.
Pdx1 Paradox--
Pdx1 exerts paradoxical effects on insulin
mRNA expression and insulin promoter activity in insulin-producing
cells and non- -cells (40, 50-56). The ectopic expression of Pdx1 in
non- -cells resulted in the induction of insulin generation (29, 50)
or transactivation of insulin promoter activity (40, 51-55).
Consistent with previous studies in insulin-producing -cells (52,
56), we demonstrated that overexpression of Pdx1 did not increase, but
even reduced, the insulin mRNA levels in INS-1-derived subclones.
It has been hypothesized that the suppressive effect of Pdx1 in
-cells is due to cooperative interactions between Pdx1 and other
transcription factors (53-57). The present study showed that
overexpression of Pdx1 in INS-1 cells also raised the mRNA level of
the -cell-restricted transcription factor Nkx6.1, known as a potent
transcriptional repressor of the intact insulin promoter (22, 25). The
negative feedback mechanism of Nkx6.1 provides an alternative
explanation for the inhibitory effect of Pdx1 in -cells.
The relevance of the increase of Nkx6.1 may also explain the
paradoxical effect of Pdx1 on glucagon promoter activity. We showed
that induction of Pdx1 in INSr cells dramatically suppressed the
glucagon promoter activity and eventually eliminated the expression of
glucagon mRNA and protein. In contrast, the ectopic expression of
Pdx1 in TC1 cells, predominantly expressing glucagon, did not
inhibit glucagon gene transcription.3 Nkx6.1 is
expressed in the insulin-producing -cell lines, including INS-1-derived subclones, but not in the -cell lines such as TC1 cells (21, 25). It is therefore likely that Nkx6.1, induced by Pdx1
(17, 25, and the present study), may indeed function as a potent
transcriptional repressor (22) and contribute to the inhibitory effect
of Pdx1 on glucagon gene transcription. However, this hypothesis cannot
explain why targeted disruption of mouse Nkx6.1 gene did not
cause increased -cell mass (16). Although we found that Pdx1 is
capable of binding the glucagon G1 element, the binding activity is not
required for the suppressive function of Pdx1 on the glucagon
promoter.3 Protein-protein interactions with other
transcription factors including Pax6 could also contribute to the
transcriptional repression of glucagon.3 Pax4, a
transcriptional repressor of the glucagon promoter (23, 24), is
essential for / -cell development (15) and is expressed transiently in the differentiating fetal -cells but not in the differentiated adult -cells (25). Although we found that Pdx1 alone
did not have any significant effect on the Pax4 mRNA expression, we
cannot rule out the possibility that Pdx1 suppresses glucagon promoter
activity through synergistic interaction with Pax4.
Overexpression of Pdx1 Raises Cellular Insulin Content without
Increasing Insulin mRNA Expression--
Another intriguing
function of Pdx1 is the increase in cellular insulin content, without
affecting insulin mRNA levels. We therefore suggest that Pdx1 may
also regulate the biosynthesis of insulin or the formation or
maturation of insulin granules.
Pdx1 Is Required for Maintaining Insulin Expression--
The
ectopic expression of Pdx1 alone in glucagonoma cells in
vitro (29) and in mouse hepatocytes in vivo (50)
resulted in induction of insulin production, suggesting that
Pdx1 is a master gene in the regulation of insulin
expression. We demonstrated here that dominant-negative suppression of
Pdx1 function in INS-1 cells caused a drastic reduction, but not
complete elimination, of the insulin mRNA expression, insulin
immunofluorescence staining, and cellular insulin content. Our results
are in agreement with the previous in vivo study of Ahlgren
et al. (17), who showed that -cell-specific inactivation
of the mouse Pdx1 gene resulted in up to 90% reduction in
the pancreatic insulin content. We thus conclude that Pdx1 is required
for maintaining insulin expression.
Loss of Pdx1 Function rather than Expression of Brain4 Is the
Prerequisite for -Cell Differentiation--
The absence of Pdx1 and
the specific expression of brain4 are the hallmarks of differentiated
-cells. The present study provided profound evidence that loss of
Pdx1 function rather than expression of brain4 is the determining
factor for -cell differentiation. We showed that induction of
DN-Pdx1 in INSr and INSr cells not only markedly repressed
insulin expression but also caused pronounced expression of glucagon.
We also performed immunofluorescence double labeling to show that
dominant-negative suppression of Pdx1 function converted the
insulin-producing -cell lineage to the -cell-dominated phenotype.
In contrast, induction of brain4 in INSr cells initiated only
detectable amounts of glucagon, without inhibiting the
-cell-specific gene pattern. The expression of endogenous brain4 in
INSr cells may partially explain the glucagon production.
The -cell-specific disruption of Pdx1 in vivo shifted the
/ cell ratio from 5:1 to 1:1 (17), which seems moderate in comparison to the 90% conversion of -cells to -cells in our study. The discrepancy may be due to the slower proliferation and
neogenesis or to less differentiation plasticity of islet -cells
in vivo.
Pdx1-specific Patterns of Gene Expression--
We found that the
-cell genes encoding insulin, IAPP, Glut2, and Nkx6.1 are
Pdx1-specific target genes. Dominant-negative suppression of Pdx1
function drastically and selectively reduced the expression of these
mRNA species. Although it has been reported that Pdx1 binds to the
Pax4 promoter (26), we showed that Pdx1 alone is not sufficient to
regulate Pax4 mRNA expression. Glucokinase expression is not
restricted to islet -cells although it is less abundant in -cells
(58). We demonstrated that the mRNA expression of glucokinase is
completely unresponsive to Pdx1 regulation. This concurs with a
previous study on transgenic mice (17). These results contrast with the
earlier claims that Pdx1 regulates the glucokinase gene (46).
Conclusion--
We conclude that Pdx1 is required for maintaining
the expression of -cell-specific genes and -cell lineage
differentiation. Loss of Pdx1 function rather than expression of brain4
is the prerequisite for -cell differentiation.
 |
ACKNOWLEDGEMENTS |
We are grateful to D. Cornut-Harry, Y. Dupre,
G. Chaffard, C. Bartley, and E.-J. Sarret for expert technical
assistance. We are indebted to Drs. P. B. Iynedjian (glucokinase
cDNA and INS-r3 and -r9 cells), E. Edlund (Pdx1 cDNA and
antibody), S. Saule (Pax6 cDNA), M. S. German (Cdx-2/3
cDNA), B. Thorens (GLUT-2 cDNA), H. Bujard (PUHD 10-3 vector),
and N. Quintrell (pTKhygro plasmid). We also thank Dr. S. Seino for
kindly providing the MIN6-m9 clone.
 |
FOOTNOTES |
*
This work was supported by Swiss National Science Foundation
Grant Number 32-49755.96, the Institute for Human Genetics and Biochemistry, the Berger Foundation, the Carlos and Elsie de Reuters Foundation, and the Juvenile Diabetes Foundation International, New
York.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence may be addressed: Division de Biochimie
Clinique et de Diabétologie Expérimentale, Départment
de Médecine Interne, Center Médical Universitaire,
CH-1211 Geneva 4, Switzerland. Tel.: 41 22 702 5548; Fax: 41 22 702 5543; E-mail: Haiyan. Wang@medicine.unige.ch or
Claes.Wollheim@medicine.unige.ch.
Published, JBC Papers in Press, April 17, 2001, DOI 10.1074/jbc.M101233200
2
H. Wang and C. B. Wollheim,
unpublished data.
3
B. Ritz-Laser, submitted for publication.
 |
ABBREVIATIONS |
The abbreviations used are:
DN, dominant-negative;
rtTA, reverse tetracycline-dependent
transactivator;
PCR, polymerase chain reaction;
EMSA, electrophoretic
mobility shift assay;
IAPP, islet amyloid polypeptide;
DOX, doxycycline.
 |
REFERENCES |
| 1.
|
Orci, L.
(1982)
Diabetes
31,
538-565
|
| 2.
|
Apelqvist, A.,
Li, H.,
Sommer, L.,
Beatus, P.,
Anderson, D. J.,
Honjo, T.,
Hrabe de Angelis, M.,
Lendahl, U.,
and Edlund, H.
(1999)
Nature
400,
877-881
|
| 3.
|
Gradwohl, G.,
Dierich, A.,
LeMeur, M.,
and Guillemot, F.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
1607-1611
|
| 4.
|
Herrera, P. L.
(2000)
Development
127,
2317-2322
|
| 5.
|
Jensen, J.,
Heller, R. S.,
Nielsen, T. F.,
Pedersen, E. E.,
Lindsell, C.,
Weinmaster, G.,
Madsen, O. D.,
and Serup, P.
(2000)
Diabetes
49,
163-176
|
| 6.
|
Schwitzgebel, V. M.,
Scheel, D. W.,
Conners, J. R.,
Kalamaras, J.,
Lee, J. E.,
Anderson, D. J.,
Sussel, L.,
Johnson, J. D.,
and German, M. S.
(2000)
Development
127,
3533-3542
|
| 7.
|
Jonsson, J.,
Carlsson, L.,
and Edlund, H.
(1994)
Nature
371,
606-609
|
| 8.
|
Offield, M. F.,
Jetton, T. L.,
Labosky, P. A.,
Ray, M.,
Stein, R.,
Magnuson, M. A.,
Hogan, B. L. M.,
and Wright, C. V. E.
(1996)
Development
122,
983-995
|
| 9.
|
Stoffers, D. A.,
Zinkin, N. T.,
Stanojevic, V.,
Clarke, W. L.,
and Habener, J. F.
(1997)
Nat. Genet.
15,
106-110
|
| 10.
|
Naya, F. J.,
Huang, H. P.,
Qui, Y.,
Mutoh, H.,
DeMayo, F. J.,
Leiter, A. B.,
and Tsai, M. J.
(1997)
Genes Dev.
11,
2323-2334
|
| 11.
|
Ahlgren, U.,
Pfaff, S. L.,
Jessell, T. M.,
Edlund, T.,
and Edlund, H.
(1997)
Nature
385,
257-260
|
| 12.
|
Sussel, L.,
Kalamaras, J.,
Hartigan-O'Connor, D. J.,
Meneses, J. J.,
Pedersen, R. A.,
Rubenstein, J. L.,
and German, M. S.
(1998)
Development
125,
2213-2221
|
| 13.
|
Sander, M.,
Neubuser, A.,
Kalamaras, J.,
Ee, H. C.,
Martin, G. R.,
and German, M. S.
(1997)
Genes Dev.
11,
1662-1673
|
| 14.
|
St-Onge, L.,
Sosa-Pineda, B.,
Chowdhury, K.,
Mansouri, A.,
and Gruss, P.
(1997)
Nature
387,
406-409
|
| 15.
|
Sosa-Pineda, B.,
Chowdhury, K.,
Torres, M.,
Oliver, G.,
and Gruss, P.
(1997)
Nature
386,
399-402
|
| 16.
|
Sander, M.,
Sussel, L.,
Conners, J.,
Scheel, D.,
Kalamaras, J.,
Dela Cruz, F.,
Schwitzgebel, V.,
Hayes-Jordan, A.,
and German, M.
(2000)
Development
127,
5533-5540
|
| 17.
|
Ahlgren, U.,
Jonsson, J.,
Jonsson, L.,
Simu, K.,
and Edlund, H.
(1998)
Genes Dev.
12,
1763-1768
|
| 18.
|
Hussain, M. A.,
Lee, J.,
Miller, C. P.,
and Habener, J. F.
(1997)
Mol. Cell. Biol.
17,
7186-7194
|
| 19.
|
Larsson, L. I.,
Madsen, O. D.,
Serup, P.,
Jonsson, J.,
and Edlund, H.
(1996)
Mech. Dev.
60,
175-184
|
| 20.
|
Serup, P.,
Petersen, H. V.,
Pedersen, E. E.,
Edlund, H.,
Leonard, J.,
Petersen, J. S.,
Larsson, L. I.,
and Madsen, O. D.
(1995)
Biochem. J.
310,
997-1003
|
| 21.
|
Jensen, J.,
Serup, P.,
Karlsen, C.,
Nielsen, T. F.,
and Madsen, O. D.
(1996)
J. Biol. Chem.
271,
18749-18758
|
| 22.
|
Mirmira, R. G.,
Watada, H.,
and German, M. S.
(2000)
J. Biol. Chem.
275,
14743-14751
|
| 23.
|
Fujitani, Y.,
Kajimoto, Y.,
Yasuda, T.,
Matsuoka, T.-A.,
Kaneto, H.,
Umayahara, Y.,
Fujita, N.,
Watada, H.,
Miyazaki, J.-I.,
Yamasaki, Y.,
and Hori, M.
(1999)
Mol. Cell. Biol.
19,
8281-8291
|
| 24.
|
Smith, S. B.,
Ee, H. C.,
Conners, J. R.,
and German, M. S.
(1999)
Mol. Cell. Biol.
19,
8272-8280
|
| 25.
|
Watada, H.,
Mirmira, R. G.,
Leung, J.,
and German, M. S.
(2000)
J. Biol. Chem.
275,
34224-34230
|
| 26.
|
Smith, S. B.,
Watada, H.,
Scheel, D. W.,
Mrejen, C.,
and German, M. S.
(2000)
J. Biol. Chem.
275,
36910-36919
|
| 27.
|
Madsen, O. D.,
Andersen, L. C.,
Michelsen, B.,
Owerback, D.,
Larsson, L.-I.,
Lernmark, A.,
and Steiner, D. F.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
6652-6656
|
| 28.
|
Madsen, O. D.,
Karlsen, C.,
Nielsen, E.,
Lund, K.,
Kofod, H.,
Welinder, B.,
Rehfeld, J. F.,
Larsson, L.-I.,
Steiner, D. F.,
Holst, J. J.,
and Michelsen, B. K.
(1993)
Endocrinology
133,
2022-2030
|
| 29.
|
Serup, P.,
Jensen, J.,
Andersen, F.,
Jorgensen, M. C.,
Blume, N.,
Holst, J. J.,
and Madsen, O. D.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
9015-9020
|
| 30.
|
Wang, H.,
Maechler, P.,
Antinozzi, P. A.,
Hagenfeldt, K. A.,
and Wollheim, C. B.
(2000)
J. Biol. Chem.
17,
35953-35959
|
| 31.
|
Gossen, M.,
Freundlieb, S.,
Bender, G.,
Müller, G.,
Hillen, W.,
and Bujard, H.
(1995)
Science
268,
1766-1769
|
| 32.
|
Wang, H.,
and Iynedjian, P. B.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
4372-4377
|
| 33.
|
Trimble, E. R.,
Halban, P. A.,
Wollheim, C. B.,
and Renold, A. E.
(1982)
J. Clin. Invest.
69,
405-413
|
| 34.
|
Schreiber, E.,
Matthias, P.,
Muller, M. M.,
and Schaffner, W.
(1988)
EMBO J.
7,
4221-4229
|
| 35.
|
German, M. S.,
Moss, L. G.,
Wang, J.,
and Rutter, W. J.
(1992)
Mol. Cell. Biol.
12,
1777-1788
|
| 36.
|
German, M. S.,
Wang, J.,
Chadwick, R. B.,
and Rutter, W. J.
(1992)
Genes Dev.
6,
2165-2176
|
| 37.
|
Ritz-Laser, B.,
Estreicher, A.,
Klages, N.,
Saule, S.,
and Philippe, J.
(1999)
J. Biol. Chem.
274,
4124-4132
|
| 38.
|
Wang, H.,
Antinozzi, P. A.,
Hagenfeldt, K. A.,
Maechler, P.,
and Wollheim, C. B.
(2000)
EMBO J.
19,
4257-4264
|
| 39.
|
Wang, H.,
Maechler, P.,
Hagenfeldt, K. A.,
and Wollheim, C. B.
(1998)
EMBO J.
17,
6701-6713
|
| 40.
|
Peshavaria, M.,
Henderson, E.,
Sharma, A.,
Wright, C. V. E.,
and Stein, R.
(1997)
Mol. Cell. Biol.
17,
3987-3996
|
| 41.
|
Macfarlane, W. M.,
McKinnon, C. M.,
Felton-Edkins, Z. A.,
Cragg, H.,
James, R. F. L.,
and Docherty, K.
(1999)
J. Biol. Chem.
274,
1011-1016
|
| 42.
|
Rafiq, I.,
da Silva Xavier, G.,
Hooper, S.,
and Rutter, G. A.
(2000)
J. Biol. Chem.
275,
15977-15984
|
| 43.
|
Rafiq, I.,
Kennedy, H. J.,
and Rutter, G. A.
(1998)
J. Biol. Chem.
273,
23241-23247
|
| 44.
|
Minami, K.,
Yano, H.,
Miki, T.,
Nagashima, K.,
Wang, C.-Z.,
Tanaka, H.,
Miyazaki, J.-I.,
and Seino, S.
(2000)
Am. J. Physiol.
279,
E773-E781
|
| 45.
|
Hessabi, B.,
Ziegler, P.,
Schmidt, I.,
Hessabi, C.,
and Walther, R.
(1999)
Eur. J. Biochem.
263,
170-177
|
| 46.
|
Watada, H.,
Kajimoto, Y.,
Umayahara, Y.,
Matzuoka, T.,
Kaneto, H.,
Fujitani, Y.,
Kamada, T.,
Kawamori, R.,
and Yamasaki, Y.
(1996)
Diabetes
45,
1478-1488
|
| 47.
|
Shen, C.-N.,
Slack, J. M. W.,
and Tosh, D.
(2000)
Nat. Cell Biol.
2,
879-887
|
| 48.
|
Krapp, A.,
Knofler, M.,
Frutiger, S.,
Hughes, G. J.,
Hagenbuchle, O.,
and Wellauer, P. K.
(1996)
EMBO J.
15,
4317-4329
|
| 49.
|
Edlund, H.
(1998)
Diabetes
47,
1817-1823
|
| 50.
|
Ferber, S.,
Halkin, A.,
Cohen, H.,
Ber, I.,
Einav, V.,
Goldberg, I.,
Barshack, I.,
Seijffers, R.,
Kopolovic, J.,
Kaiser, N.,
and Karasik, A.
(2000)
Nat. Med.
6,
568-572
|
| 51.
|
Glick, E.,
Leshkowitz, D.,
and Walker, M. D.
(2000)
J. Biol. Chem.
275,
2199-2204
|
| 52.
|
Marshak, S.,
Totary, H.,
Cerasi, E.,
and Melloul, D.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
15057-15062
|
| 53.
|
Marshak, S.,
Benshushan, E.,
Shoshkes, M.,
Havin, L.,
Cerasi, E.,
and Melloul, D.
(2000)
Mol. Cell. Biol.
20,
7583-7590
|
| 54.
|
Ohneda, K.,
Mirmira, R. G.,
Wang, J.,
Johnson, J. D.,
and German, M. S.
(2000)
Mol. Cell. Biol.
20,
900-911
|
| 55.
|
Petersen, H. V.,
Serup, P.,
Leodard, J.,
Michelsen, B. K.,
and Madsen, O. D.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
10465-10469
|
| 56.
|
Seijffers, R.,
Ben-David, O.,
Cohen, Y.,
Karasik, A.,
Berezin, M.,
Newgard, C. B.,
and Ferber, S.
(1999)
Endocrinology
140,
3311-3317
|
| 57.
|
Peers, B.,
Leonard, J.,
Sharma, S.,
Teitelman, G.,
and Montminy, M. R.
(1994)
Mol. Endocrinol.
8,
1798-1806
|
| 58.
|
Heimberg, H.,
De Vos, A.,
Moens, K.,
Quartier, E.,
Bouwens, L.,
Pipeleers, D.,
Van Schaftingen, E.,
Madsen, O.,
and Schuit, F.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
7036-7041
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
T. Jin
Mechanisms underlying proglucagon gene expression
J. Endocrinol.,
July 1, 2008;
198(1):
17 - 28.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Sun, L. Zhang, H. F. Gu, W. Han, M. Ren, F. Wang, B. Gong, L. Wang, H. Guo, W. Xin, et al.
Peroxisome Proliferator-Activated Receptor-{alpha} Regulates the Expression of Pancreatic/Duodenal Homeobox-1 in Rat Insulinoma (INS-1) Cells and Ameliorates Glucose-Induced Insulin Secretion Impaired by Palmitate
Endocrinology,
February 1, 2008;
149(2):
662 - 671.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Gosmain, I. Avril, A. Mamin, and J. Philippe
Pax-6 and c-Maf Functionally Interact with the {alpha}-Cell-specific DNA Element G1 in Vivo to Promote Glucagon Gene Expression
J. Biol. Chem.,
November 30, 2007;
282(48):
35024 - 35034.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. M. Keller, S. McWeeney, A. Arsenlis, J. Drouin, C. V. E. Wright, H. Wang, C. B. Wollheim, P. White, K. H. Kaestner, and R. H. Goodman
Characterization of Pancreatic Transcription Factor Pdx-1 Binding Sites Using Promoter Microarray and Serial Analysis of Chromatin Occupancy
J. Biol. Chem.,
November 2, 2007;
282(44):
32084 - 32092.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Gromada, I. Franklin, and C. B. Wollheim
{alpha}-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains
Endocr. Rev.,
February 1, 2007;
28(1):
84 - 116.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. E Cerf
Transcription factors regulating {beta}-cell function.
Eur. J. Endocrinol.,
November 1, 2006;
155(5):
671 - 679.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Wang, T. Liu, Z. Li, X. Ma, and T. Jin
Redundant and Synergistic Effect of Cdx-2 and Brn-4 on Regulating Proglucagon Gene Expression
Endocrinology,
April 1, 2006;
147(4):
1950 - 1958.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E N Fazio, M Everest, R Colman, R Wang, and C L Pin
Altered Glut-2 accumulation and {beta}-cell function in mice lacking the exocrine-specific transcription factor, Mist1
J. Endocrinol.,
December 1, 2005;
187(3):
407 - 418.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. L.M. Khoo, L. R. McQuade, M. S.R. Smith, J. G. Lees, K. S. Sidhu, and B. E. Tuch
Growth and Differentiation of Embryoid Bodies Derived from Human Embryonic Stem Cells: Effect of Glucose and Basic Fibroblast Growth Factor
Biol Reprod,
December 1, 2005;
73(6):
1147 - 1156.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Holland, L. J. Gonez, G. Naselli, R. J. MacDonald, and L. C. Harrison
Conditional Expression Demonstrates the Role of the Homeodomain Transcription Factor Pdx1 in Maintenance and Regeneration of {beta}-Cells in the Adult Pancreas
Diabetes,
September 1, 2005;
54(9):
2586 - 2595.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Wang, G. Kouri, and C. B. Wollheim
ER stress and SREBP-1 activation are implicated in {beta}-cell glucolipotoxicity
J. Cell Sci.,
September 1, 2005;
118(17):
3905 - 3915.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. C. Schisler, P. B. Jensen, D. G. Taylor, T. C. Becker, F. K. Knop, S. Takekawa, M. German, G. C. Weir, D. Lu, R. G. Mirmira, et al.
The Nkx6.1 homeodomain transcription factor suppresses glucagon expression and regulates glucose-stimulated insulin secretion in islet beta cells
PNAS,
May 17, 2005;
102(20):
7297 - 7302.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. F. Pino, D. Z. Ye, K. D. Linning, C. D. Green, B. Wicksteed, V. Poitout, and L. K. Olson
Elevated Glucose Attenuates Human Insulin Gene Promoter Activity in INS-1 Pancreatic {beta}-Cells via Reduced Nuclear Factor Binding to the A5/Core and Z Element
Mol. Endocrinol.,
May 1, 2005;
19(5):
1343 - 1360.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Iype, J. Francis, J. C. Garmey, J. C. Schisler, R. Nesher, G. C. Weir, T. C. Becker, C. B. Newgard, S. C. Griffen, and R. G. Mirmira
Mechanism of insulin Gene Regulation by the Pancreatic Transcription Factor Pdx-1: APPLICATION OF PRE-mRNA ANALYSIS AND CHROMATIN IMMUNOPRECIPITATION TO ASSESS FORMATION OF FUNCTIONAL TRANSCRIPTIONAL COMPLEXES
J. Biol. Chem.,
April 29, 2005;
280(17):
16798 - 16807.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Kaneto, Y. Nakatani, T. Miyatsuka, T.-a. Matsuoka, M. Matsuhisa, M. Hori, and Y. Yamasaki
PDX-1/VP16 Fusion Protein, Together With NeuroD or Ngn3, Markedly Induces Insulin Gene Transcription and Ameliorates Glucose Tolerance
Diabetes,
April 1, 2005;
54(4):
1009 - 1022.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Li, X. Cao, L.-X. Li, P. L. Brubaker, H. Edlund, and D. J. Drucker
{beta}-Cell Pdx1 Expression Is Essential for the Glucoregulatory, Proliferative, and Cytoprotective Actions of Glucagon-Like Peptide-1
Diabetes,
February 1, 2005;
54(2):
482 - 491.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Flock, X. Cao, and D. J. Drucker
Pdx-1 Is Not Sufficient for Repression of Proglucagon Gene Transcription in Islet or Enteroendocrine Cells
Endocrinology,
January 1, 2005;
146(1):
441 - 449.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Thomas, S. Senkel, S. Erdmann, T. Arndt, G. Turan, L. Klein-Hitpass, and G. U. Ryffel
Pattern of genes influenced by conditional expression of the transcription factors HNF6, HNF4{alpha} and HNF1{beta} in a pancreatic {beta}-cell line
Nucleic Acids Res.,
November 1, 2004;
32(19):
e150 - e150.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. R. Gauthier, T. Brun, E. J. Sarret, H. Ishihara, O. Schaad, P. Descombes, and C. B. Wollheim
Oligonucleotide Microarray Analysis Reveals PDX1 as an Essential Regulator of Mitochondrial Metabolism in Rat Islets
J. Biol. Chem.,
July 23, 2004;
279(30):
31121 - 31130.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Iype, D. G. Taylor, S. M. Ziesmann, J. C. Garmey, H. Watada, and R. G. Mirmira
The Transcriptional Repressor Nkx6.1 Also Functions as a Deoxyribonucleic Acid Context-Dependent Transcriptional Activator during Pancreatic {beta}-Cell Differentiation: Evidence for Feedback Activation of the nkx6.1 Gene by Nkx6.1
Mol. Endocrinol.,
June 1, 2004;
18(6):
1363 - 1375.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Liberzon, G. Ridner, and M. D. Walker
Role of intrinsic DNA binding specificity in defining target genes of the mammalian transcription factor PDX1
Nucleic Acids Res.,
January 2, 2004;
32(1):
54 - 64.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Suzuki, K. Tobe, Y. Terauchi, K. Komeda, N. Kubota, K. Eto, T. Yamauchi, K. Azuma, H. Kaneto, T. Taguchi, et al.
Pdx1 Expression in Irs2-deficient Mouse {beta}-Cells Is Regulated in a Strain-dependent Manner
J. Biol. Chem.,
October 31, 2003;
278(44):
43691 - 43698.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Vincent, Y. Guz, M. Rozenberg, G. Webb, M. Furuta, D. Steiner, and G. Teitelman
Abrogation of Protein Convertase 2 Activity Results in Delayed Islet Cell Differentiation and Maturation, Increased {alpha}-Cell Proliferation, and Islet Neogenesis
Endocrinology,
September 1, 2003;
144(9):
4061 - 4069.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Ber, K. Shternhall, S. Perl, Z. Ohanuna, I. Goldberg, I. Barshack, L. Benvenisti-Zarum, I. Meivar-Levy, and S. Ferber
Functional, Persistent, and Extended Liver to Pancreas Transdifferentiation
J. Biol. Chem.,
August 22, 2003;
278(34):
31950 - 31957.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Wang, P. Maechler, P. A. Antinozzi, L. Herrero, K. A. Hagenfeldt-Johansson, A. Bjorklund, and C. B. Wollheim
The Transcription Factor SREBP-1c Is Instrumental in the Development of beta -Cell Dysfunction
J. Biol. Chem.,
May 2, 2003;
278(19):
16622 - 16629.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Cao, G. Flock, C. Choi, D. M. Irwin, and D. J. Drucker
Aberrant Regulation of Human Intestinal Proglucagon Gene Expression in the NCI-H716 Cell Line
Endocrinology,
May 1, 2003;
144(5):
2025 - 2033.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Wang, K. Hagenfeldt-Johansson, L. A. Otten, B. R. Gauthier, P. L. Herrera, and C. B. Wollheim
Experimental Models of Transcription Factor-Associated Maturity-Onset Diabetes of the Young
Diabetes,
December 1, 2002;
51(90003):
S333 - 342.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Flock and D. J. Drucker
Pax-2 Activates the Proglucagon Gene Promoter But Is Not Essential for Proglucagon Gene Expression or Development of Proglucagon-Producing Cell Lineages in the Murine Pancreas or Intestine
Mol. Endocrinol.,
October 1, 2002;
16(10):
2349 - 2359.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Wang and C. B. Wollheim
ChREBP Rather than USF2 Regulates Glucose Stimulation of Endogenous L-pyruvate Kinase Expression in Insulin-secreting Cells
J. Biol. Chem.,
August 30, 2002;
277(36):
32746 - 32752.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Kaneto, G. Xu, N. Fujii, S. Kim, S. Bonner-Weir, and G. C. Weir
Involvement of c-Jun N-terminal Kinase in Oxidative Stress-mediated Suppression of Insulin Gene Expression
J. Biol. Chem.,
August 9, 2002;
277(33):
30010 - 30018.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. J. Abraham, C. A. Leech, J. C. Lin, H. Zulewski, and J. F. Habener
Insulinotropic Hormone Glucagon-Like Peptide-1 Differentiation of Human Pancreatic Islet-Derived Progenitor Cells into Insulin-Producing Cells
Endocrinology,
August 1, 2002;
143(8):
3152 - 3161.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Wang, B. R. Gauthier, K. A. Hagenfeldt-Johansson, M. Iezzi, and C. B. Wollheim
Foxa2 (HNF3beta ) Controls Multiple Genes Implicated in Metabolism-Secretion Coupling of Glucose-induced Insulin Release
J. Biol. Chem.,
May 10, 2002;
277(20):
17564 - 17570.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Hussain, C. P. Miller, and J. F. Habener
Brn-4 Transcription Factor Expression Targeted to the Early Developing Mouse Pancreas Induces Ectopic Glucagon Gene Expression in Insulin-producing beta Cells
J. Biol. Chem.,
May 3, 2002;
277(18):
16028 - 16032.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Kaneto, A. Sharma, K. Suzuma, D. R. Laybutt, G. Xu, S. Bonner-Weir, and G. C. Weir
Induction of c-Myc Expression Suppresses Insulin Gene Transcription by Inhibiting NeuroD/BETA2-mediated Transcriptional Activation
J. Biol. Chem.,
April 5, 2002;
277(15):
12998 - 13006.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. K. Chakrabarti, J. C. James, and R. G. Mirmira
Quantitative Assessment of Gene Targeting in Vitro and in Vivo by the Pancreatic Transcription Factor, Pdx1. IMPORTANCE OF CHROMATIN STRUCTURE IN DIRECTING PROMOTER BINDING
J. Biol. Chem.,
April 5, 2002;
277(15):
13286 - 13293.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|